1. Academic Validation
  2. Drug-Like Small Molecules That Inhibit Expression of the Oncogenic MicroRNA-21

Drug-Like Small Molecules That Inhibit Expression of the Oncogenic MicroRNA-21

  • ACS Chem Biol. 2023 Feb 17;18(2):237-250. doi: 10.1021/acschembio.2c00502.
Matthew D Shortridge 1 Bhawna Chaubey 1 Huanyu J Zhang 2 Thomas Pavelitz 1 Venkata Vidadala 1 Changyan Tang 1 Gregory L Olsen 1 George A Calin 2 Gabriele Varani 1
Affiliations

Affiliations

  • 1 Department of Chemistry, University of Washington, Seattle, Washington 98195, United States.
  • 2 Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States.
Abstract

We report the discovery of drug-like small molecules that bind specifically to the precursor of the oncogenic and pro-inflammatory microRNA-21 with mid-nanomolar affinity. The small molecules target a local structure at the Dicer cleavage site and induce distinctive structural changes in the RNA, which correlate with specific inhibition of miRNA processing. Structurally conservative single nucleotide substitutions eliminate the conformational change induced by the small molecules, which is also not observed in other miRNA precursors. The most potent of these compounds reduces cellular proliferation and miR-21 levels in Cancer cell lines without inhibiting kinases or classical receptors, while closely related compounds without this specific binding activity are inactive in cells. These molecules are highly ligand-efficient (MW < 330) and display specific biochemical and cellular activity by suppressing the maturation of miR-21, thereby providing an avenue toward therapeutic development in multiple diseases where miR-21 is abnormally expressed.

Figures
Products